Company

Travere Therapeutics Inc.

United States

Employees: 310

CEO: Dr. Eric M. Dube Ph.D.

NASDAQ: TVTX -8.89%

Market Cap

$1.67 Billion

USD as of Jan. 1, 2025

Market Cap History

Travere Therapeutics Inc. market capitalization over time

Evolution of Travere Therapeutics Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Travere Therapeutics Inc.

Detailed Description

Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Top 1-year algo backtest: +327.04%

$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Financials

Last Financial Reports Date Dec. 31, 2023
Revenue TTM $145.2 M
EBITDA $-338,214,016
Gross Profit TTM $133.8 M
Profit Margin -76.70%
Operating Margin -183.85%
Quarterly Revenue Growth 53.60%
Financial Reports & Statistics

Stocks & Indices

Travere Therapeutics Inc. has the following listings and related stock indices.


Stock: NASDAQ: TVTX wb_incandescent

Details

United States